By targeting natural hotspots with novel allosteric chemistry, important disease biology can be unlocked for the first time.
To date, HotSpot Therapeutics has successfully uncovered and targeted natural hotspots across multiple protein classes, including kinases, transcription factors and E3 ligases. Pathways and targets long abandoned by drug developers and believed to be undruggable are now within our reach. We are poised to bring first- and/or best-in-class medicines to patients with cancer and autoimmune diseases.
Our platform has allowed us to deliver differentiated small molecule allosteric inhibitors that address some key challenges for targets with deep genetic and/or biologic validation.
Hard to drug
Non-selective
Poor target coverage
First C-CBL selective
Picomolar affinity
Durable target binding (>24hrs)
Poor selectivity
Poor target coverage
Selective vs PKC-delta
Intrinsic degraders
Tissue targeting
Undrugged with
small molecules
First and only antagonists
TF selective
Enables other TF class
Our wholly owned pipeline is further enabled by a focus on biomarker-driven, patient-targeted approaches in oncology and autoimmune diseases. We are also poised to deliver a continuous stream of new clinical candidates and value-generating data in early clinical development.
